| Gene symbol | CLDN18 | Synonyms | SFTA5, SFTPJ | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q22.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | claudin 18 | ||||
| GTO ID | GTC3538 |
| Trial ID | NCT05981235 |
| Disease | Gastrointestinal Tumor |
| Altered gene | CLDN18 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AZD6422|CLDN18.2 CAR-T |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | FTiH, Phase 1 Investigator-Initiated Trial (IIT) to Evaluate the Safety, Feasibility, Cellular Kinetics, and Preliminary Antitumor Activity of AZD6422 in Adult Participants With Advanced or Metastatic CLDN18.2+ GI Tumors |
| Year | 2023 |
| Country | China |
| Company sponsor | Peking University |
| Other ID(s) | D9540C00001 |
| Cohort 1 | |||||||
|
|||||||